公募基金新发"潮涌" Choice数据显示，截至8月19日，7月以来新成立的基金达221只，其中权益类基金（混合型、股票型基 金）数量占比超七成，是新发"主力军"。 7月以来新发基金数量情况 （截至8月19日） ◎记者 朱妍 市场行情活跃，公募基金发行愈发火热。数据显示，7月以来，新成立的基金中权益类数量占比超七 成。同期，逾50只权益类基金提前结束募集，以便快速成立后入市。业内人士认为，近期公募新发市场 的火热，与A股市场走势强劲、投资者信心提升、权益类基金业绩较好有关。在基金公司加码权益类产 品布局的同时，不少资金也在积极借"基"入市，有望为市场带来更多增量资金。 快速结束募集入市"抢筹" 公募增量资金正以较快节奏进入市场。 数据显示，下半年以来，已有71只基金提前结束募集，其中52只是权益类基金，占比达73%。如8月18 日启动发行的招商中证机器人ETF，原计划于8月29日结束募集，最后仅发售1日；易方达国证通用航空 产业ETF、嘉实恒生港股通科技主题ETF等指数基金同样在发行后缩短了募集期。 "今年以来市场轮动较快，下半年结构性机会依然显著。因此我们也在争分夺秒，希望能更快地成立基 金，以把握合适的入 ...

Core Insights - The second batch of new floating-rate funds, including the China Europe Core Smart Mixed Fund, has seen strong market demand, with the first fund raising over 2 billion yuan and ending its fundraising early [2][3][4] - The China Securities Regulatory Commission (CSRC) has been promoting the development of public funds, including floating-rate fund trials, which has led to a total of 26 funds in the first batch raising over 25.8 billion yuan [2][6] - The second batch consists of 12 funds, including 2 equity funds and 10 mixed funds, focusing on various sectors such as pharmaceuticals and high-end manufacturing [6][7] Fund Characteristics - The China Europe Core Smart Mixed Fund features a "benchmark + floating" fee structure, which is attractive to investors, and includes a quarterly dividend distribution mechanism [4][6] - The fee structure for the second batch of floating-rate funds is more diversified, with three tiers based on performance, allowing for a more tailored approach to investor needs [6][7] - The second batch's focus on specific industry themes is expected to better align with international capital interests, potentially attracting more foreign investment [7] Market Trends - The early closure of fundraising for two funds indicates a growing acceptance and recognition of floating-rate funds in the market [4][8] - Investors are becoming increasingly cautious and are focusing on fund managers' capabilities and fee structures, which may lead to a more competitive environment for fund management [7][8] - The floating-rate fund model aligns the interests of fund managers and investors, potentially leading to better performance and lower costs for investors [7][8] Challenges Ahead - Despite the advantages of floating-rate funds, challenges remain, including market volatility and the need for investor education regarding fee structures [8][9] - The long-term success of floating-rate funds will depend on their ability to deliver consistent performance and gain market trust [9]

Core Viewpoint - The issuance of new floating-rate funds is gaining momentum in the market, with the E Fund Value Return Mixed Fund raising over 2 billion yuan and ending its subscription early [2][4][6]. Fund Issuance Details - The E Fund Value Return Mixed Fund announced the early closure of its fundraising on August 13, having started on August 4, with a target end date originally set for August 20, 2025 [4][6]. - This fund is part of the second batch of floating-rate funds, which includes the China Europe Core Select Mixed Fund and the Jianxin Medical Innovation Stock Fund, both of which also launched on the same day [4][6]. - The second batch of floating-rate funds has seen two out of three funds reach a fundraising scale of over 2 billion yuan, indicating a significant increase in market interest compared to the first batch [6]. Market Trends - The approval and issuance of new floating-rate products have accelerated since May 2023, following the China Securities Regulatory Commission's action plan to promote high-quality development of public funds [8]. - The first batch of 26 floating-rate funds launched on May 27, raising a total of over 25.8 billion yuan [9]. - As of August 12, most of the first batch of floating-rate funds have achieved positive returns, with some funds showing significant net asset value growth since their inception [10]. Future Outlook - Analysts suggest that the positive performance of the A-share market, particularly the Shanghai Composite Index breaking the 3600-point mark, is likely to attract more capital into the market as new floating-rate products are issued [11].

Core Viewpoint - The recent launch of new floating fee rate funds by major public fund companies indicates a growing trend in the market, with a focus on innovative investment strategies and enhanced investor experience [2][8]. Fund Launch and Features - Three new funds have been launched: E Fund Value Return Mixed, China Europe Core Select Mixed, and CCB Medical Innovation Stock, with subscription deadlines on August 20, August 15, and August 22 respectively [2]. - CCB Medical Innovation Stock has a fundraising cap of 3 billion yuan, while the other two funds do not have a limit [2]. - All three funds can invest in Hong Kong stocks, allowing for A+H share market allocation, with a maximum of 50% of stock assets in Hong Kong Stock Connect [2]. Innovative Dividend Mechanism - The China Europe Core Select Mixed fund has introduced a "quarterly dividend upon meeting standards" clause, allowing investors to receive cash dividends without redeeming their shares if the profit per share exceeds 0.01 yuan [3][4]. - This mechanism aims to enhance the holding experience for investors, although it is emphasized that dividends do not directly correlate with the fund's management quality [4]. Performance Benchmark Design - Each fund has a clearly defined performance benchmark reflecting its investment strategy: - E Fund Value Return Mixed targets a combination of indices including 55% from the CSI 800 Index and 20% from the CSI Hong Kong Stock Connect Composite Index [5]. - China Europe Core Select Mixed focuses primarily on the CSI 800 Index with an 80% weight [5]. - CCB Medical Innovation Stock emphasizes industry attributes with 70% from the CSI Medical and Health Index [5][6]. Fee Structure - All three funds adopt a "benchmark + floating" fee management model, with a base management fee of 1.2% [7]. - The fee structure includes incentives for performance, with higher fees applicable when returns exceed the benchmark and reduced fees when underperforming [7]. - This floating mechanism is designed to protect investors, only applying to those who hold their investments for over a year [7]. Market Expansion and Policy Influence - The rapid expansion of floating fee rate funds is driven by clear regulatory guidance, with the China Securities Regulatory Commission mandating that such products should constitute at least 60% of the issuance from leading institutions [8]. - The first batch of 26 floating fee rate funds was quickly approved and launched, raising a total of 25.9 billion yuan by July 21, significantly higher than the average for active equity funds [8]. - The introduction of CCB Medical Innovation Stock marks a strategic expansion into sectors like healthcare and high-end manufacturing, indicating a trend towards more innovative product offerings [9].

Core Viewpoint - The launch of the second batch of performance-based floating management fee rate funds by three public fund institutions reflects a trend towards aligning the interests of fund managers and investors through differentiated fee structures [1][3]. Fund Structure - The newly issued funds, including 中欧核心智选混合, 易方达价值回报混合, and 建信医疗创新股票, will have a management fee structure that includes a fixed management fee of 0.6% per year, a conditional management fee of 0.6% per year, and an excess management fee of 0.3% per year, depending on the holding period and annualized return [2][3]. - If investors hold their shares for less than one year, the management fee will be 1.2% per year. For holding periods of one year or more, the management fee will vary based on the annualized return, with a maximum of 1.5% per year for returns exceeding the benchmark by more than 6% [2][3]. Investor Experience - The new floating management fee model aims to encourage long-term investment by allowing investors to feel the impact of their returns on fees, promoting a "more earned, more paid; less earned, less paid" philosophy [3]. - 中欧核心智选混合 will implement a "quarterly distribution upon meeting standards" clause, allowing investors to receive cash dividends without redeeming their shares, enhancing the holding experience [5]. Performance Benchmark - The performance benchmarks for the funds have been clearly defined, with 易方达价值回报混合 linked to a composite of various indices, 中欧核心智选混合 primarily tied to the 中证800 index, and 建信医疗创新股票 associated with the 中证医药卫生指数 [4]. Industry Context - The launch of these funds aligns with the China Securities Regulatory Commission's initiative to promote high-quality development in the public fund industry, emphasizing the establishment of floating management fee mechanisms linked to fund performance [5].

Core Insights - A total of 19 public funds have launched their initial fundraising on August 4, including three products from the second batch of new floating-rate funds: E Fund Value Return Mixed, China Europe Core Select Mixed, and Jianxin Medical Innovation Stock [1] Fund Details - China Europe Core Select Mixed is set to end its fundraising on August 15, E Fund Value Return Mixed on August 20, and Jianxin Medical Innovation Stock on August 22 [1] - Jianxin Medical Innovation has a fundraising cap of 3 billion yuan [1] Fund Management - E Fund Value Return is managed by Tang Bolun, Jianxin Medical Innovation by Ma Muqing, and China Europe Core Select by Zhang Cong and Song Ting [1] Fund Approval and Themes - The second batch of new floating-rate funds was approved on July 24, covering various industry themes such as pharmaceuticals, manufacturing, and high-end equipment, along with initiator funds [1] - Among the new products, there are 2 stock-type funds and 10 equity-mixed funds, including: Invesco Great Wall High-end Equipment Stock, Jianxin Medical Innovation Stock, Bank of China Quality Emerging Mixed, Ping An Research-Driven Mixed, Southern Ruijing Mixed, Oriental Red Medical Innovation Mixed, E Fund Value Return Mixed, Huatai-PB Manufacturing Theme Mixed, Guotai Quality Core Mixed, China Europe Core Select Mixed, and Morgan Huikai Growth Mixed [1]

Core Viewpoint - The second batch of 11 floating fee rate new funds has been submitted for approval, expanding from the first batch of 26 funds, and includes both broad market selection products and industry-specific thematic products, particularly in sectors like pharmaceuticals, high-end equipment, and manufacturing [1][2]. Group 1: Fund Characteristics - The new floating fee rate funds are designed to meet investor demand for quality technology investment tools and leverage the research team's expertise in the technology growth sector [1][6]. - The second batch includes a diverse range of products, moving from broad market strategies to more specialized thematic strategies, indicating a richer variety of offerings to cater to different investor preferences [2][3]. - The management fee structure remains at three tiers: 1.2% (benchmark), 1.5% (upward adjustment), and 0.6% (downward adjustment), with specific conditions for fee application based on fund performance relative to benchmarks [2][3]. Group 2: Industry Focus - High-end equipment and pharmaceuticals are highlighted as key sectors for the new thematic funds, with high-end equipment being a core support of the modern industrial system and a significant part of technology investment [6]. - The pharmaceutical sector, particularly the innovative drug segment, is experiencing rapid revenue growth, with companies poised to enter international markets, indicating substantial future opportunities [6]. - The focus on biotechnology companies with global market potential and traditional pharmaceutical companies undergoing successful transformations is emphasized as a strategic investment direction [6].